ArticleBMC psychiatry2026
The interplay of niacin skin flush response with plasma MDA, TNOS, iNOS and clinical symptom severity in chronic schizophrenia.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMultiple studies have consistently reported elevated oxidative stress and an impaired niacin skin flush response in patients with schizophrenia. This study aimed to compare differences in oxidative stress levels and the niacin skin flush response between patients stratified by the intensity of their response and healthy controls, and to analyze the correlations among oxidative stress markers, the niacin response, and clinical symptoms within the different response subgroups.
methodsA cross-sectional case-control design was employed. Fifty patients with chronic schizophrenia and 50 demographically matched healthy controls were enrolled. Plasma levels of malondialdehyde (MDA), total nitric oxide synthase (TNOS), and inducible nitric oxide synthase (iNOS) were measured in all participants, and the niacin skin flush response was assessed. Symptom severity in patients was rated using the Positive and Negative Syndrome Scale (PANSS). Based on the intensity of the niacin response, patients were further divided into high-response and low-response subgroups. Regression analysis was used to explore the associations among oxidative stress indicators, the niacin response, and clinical symptoms.
resultsMDA levels were significantly higher in the patient group than in the control group, whereas both TNOS and iNOS levels were significantly lower. The pattern of associations among oxidative stress markers, the niacin skin flush response, and clinical symptoms differed across response subgroups. These relationships may be influenced by factors such as sex, body mass index (BMI), age, and the dosage of antipsychotic medication.
conclusionPatients with chronic schizophrenia exhibit abnormalities in oxidative stress and show individual variability in the niacin skin flush response. The intensity of the niacin response may be associated with factors such as sex, BMI, age, and medication, leading to significant differences in the relationships among variables across subgroups in regression analysis. The results suggest that oxidative stress may be involved in the pathophysiological processes of schizophrenia, and that niacin sensitivity may reflect the level of oxidative stress in the body and correlate with different clinical symptomatic profiles. CLINICAL TRIAL: No applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.